Merck Wards Off More Januvia Infringers In India
This article was originally published in Scrip
Executive Summary
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride), or hope to introduce copies of these on the domestic market, infringing on its patents.
You may also be interested in...
Januvia Generics Arrive In India
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?
Januvia Generics Arrive: Can MSD Defend Its Turf In India?
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?
Merck-Teva Legal Wrangle Over Januvia "R&D" In India
Merck & Co continues to keep a hawk eye on alleged infringement activities in India pertaining to its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). It has hauled Teva to court for allegedly manufacturing and selling sitagliptin, though the Israeli multinational has claimed that its efforts were geared only towards regulatory submissions.